Corvus Pharmaceuticals
CRVS
38 hedge funds and large institutions have $58.1M invested in Corvus Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 6 closing their positions.
151% more call options, than puts
Call options by funds: $361K | Put options by funds: $144K
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
0% more funds holding
Funds holding: 38 → 38 (0)
3.27% less ownership
Funds ownership: 61.4% → 58.13% (-3.3%)
16% less capital invested
Capital invested by funds: $69M → $58.1M (-$11M)
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$805K |
| 2 |
TI
Telemetry Investments
New York
|
+$761K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$151K |
| 4 |
Truist Financial
Charlotte,
North Carolina
|
+$84.6K |
| 5 |
Capstone Investment Advisors
New York
|
+$71.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$2.18M |
| 2 |
Millennium Management
New York
|
-$1.05M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$588K |
| 4 |
CA
CHI Advisors
New York
|
-$372K |
| 5 |
BlackRock
New York
|
-$369K |
CRVS Hedge Fund Activity: Q4 2020 in Review
38 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q4 2020, worth a combined $58.1M — down 16% from $69M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CRVS positions and 6 closed out — a net gain of 1 holder — while 7 added to existing stakes and 13 trimmed.
The largest buyer was BVF Inc, adding an estimated $805K. The largest seller was Novo Holdings A/S, cutting an estimated $2.18M.
- 38 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $58.1M of Corvus Pharmaceuticals stock for Q4 2020, down 16% quarter-over-quarter.
- 7 funds opened new Corvus Pharmaceuticals positions in Q4 2020 and 6 closed out, a net change of +1 holder.
- The largest Corvus Pharmaceuticals buyer in Q4 2020 was BVF Inc, an estimated $805K added.
- The largest Corvus Pharmaceuticals seller in Q4 2020 was Novo Holdings A/S, an estimated $2.18M sold.
Based on aggregated 13F filings for Q4 2020.